OBJECTIVES: The aim of this study is to evaluate in a descriptive way the self-informed quality of life in a group of patients with Non-Small Cell Lung Cancer who previously failed to chemotherapy and currently are treated with Erlotinib vs Taxanes METHODS: An experimental, observational, transversal, comparative and multicentric study was done to evaluate the quality of life with the application of two validated research instruments: EORTC QLQ-C30 and EORTC QLQ-LC13, to patients with NSCLS who previously failed to chemotherapy and currently are treated with Erlotiniband or Taxanes, 24 patients were surveyed for each comparator. A descriptive analysis was done using central tendency measurements, frequencies, and a variance analysis (ANOVA) to compare quality of life differences with the two different therapies. RESULTS: Global quality of life index for patients in treatment with Erlotinib is 0.81 and taxanes 0.62. The consistency in the answers was corroborated using a variance analysis (ANOVA), Erlotinib 0.8156 vs Taxanos 0.6281 NOVA Pr > F <0.0001 Tukey <0.0001. CONCLUSIONS: The use of Erlotinib in patients with NSCLS who previously failed to first line chemotherapy provides a better quality of life and general state of health than therapies based on Taxanes